Effect of SGLT2 inhibitors in the management of moroccan patients with heart failure with reduced ejection fraction

Abstract

Abstract Introduction Chronic heart failure became more frequent in Moroccan patients. The aim of our study is to determinate the benefit of SGLT2 inhibitors in patients with heart failure with reduced ejection (HFrEF) fraction. Materials and methods It's a prospective study included 140 patients with heart failure with reduced ejection fraction (HFrEF), admitted in Cardiac Rehabilitation unit, Cardiology centre, Morocco. All of them had clinical evaluation, echocardiography and cardio respiratory evaluation. Results The average of patients was 67,13 ± 7,4 years with male predominance, they have more than three cardiovascular risk factors dominated by diabetes and hypertension, coronary artery disease is the most frequent etiology, they had reduced ejection fraction (EF : 32 ± 6,4%). After 20 sessions of exercise training and therapeutic education specially optimisation of treatment by introducing precociously Quadruple theray ( Betablockers, MRA, ARNi, and SGLT2inhibitors), patients have a good quality of life, they become less symptomatic (dyspnea class III to II of NYHA); they significantly improve 6 min walk test and maximal work load (from 59, 6 ± 10,7 to 71, 2 ± 19,2 watt) and VO2max (from 14,2 ± 5,3 to 19,7 ± 6,9 ml/kg/min) Conclusion This study demonstrated that exercise training and optimisation of treatment specially SGLT2inhibitors is clearly benefit for patients with HFrEF to improve their exercise capacities and quality of life